Lyophilized peptide stability depends on 6+ interacting factors — not temperature alone. What the formulation science actually says about shelf life.
Bacteriostatic water isn’t just filler — formulation science shows diluent choice governs reconstituted stability. The complete research breakdown.
Peptide vial vs capsule: preclinical data on BPC-157 and TB-500 shows bioavailability is compound-specific. The route decision is more complex than you think.
Sermorelin GHRH analog dosing models reviewed: dose-response data, PK comparisons, and mechanistic evidence across pituitary, neuro, and cardiac axes.
Most research peptides fail orally — but a few don’t. Learn the formulation science behind oral capsule delivery and which compounds survive the GI tract.
How to read a peptide Certificate of Analysis — decode purity methods, spot HPLC failure modes, and know exactly what a CoA does and doesn’t confirm.
Oral vs injectable peptides — bioavailability isn’t the whole story. Preclinical data reveals when route of administration actually changes outcomes.
Peptides can’t survive the gut — that was the consensus. Preclinical data from 2020–2026 says the formulation science has caught up.
Where to buy BPC-157 capsules in 2026? The preclinical data on oral bioactivity is compelling — if the sourcing standards hold up. Here’s the checklist.
Khavinson Triple stacks three bioregulators across distinct aging axes. Preclinical data on telomere biology, neuroprotection, and BDNF signalling.
THE STACK · RESEARCH NOTES
125 papers across 8 compound categories.